Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,369 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder OR higher carbohydrate Clear all
Recruiting Phase 3 Interventional

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07234032
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Naples, Florida • Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

NCT05095311
View directory record Official record
Conditions
Exercise-induced Arterial Hypoxemia
Interventions
Cetirizine HCl, Placebo
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 14, 2026, 11:23 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Effects of Dietary Supplementation on Serum Protein Glycosylation

NCT05040204
View directory record Official record
Conditions
Healthy
Interventions
Monosaccharide Powder, Placebo Comparator
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

NCT00152971
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Thromboembolism
Interventions
Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion, Dabigatran Dose 2 - day 1, Enoxaparin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
59
States / cities
Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 14, 2026, 11:23 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

NCT03150004
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Cladribine and Cytarabine (CLLDAC) Regimen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Recruiting Phase 2 Interventional

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT03418038
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions
Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine
Dietary Supplement · Drug · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
4
States / cities
Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Nudging High Emergency Department Utilizers to Consider Non-emergent Healthcare Resources

NCT06818825
View directory record Official record
Conditions
Emergency Service, Hospital
Interventions
Automated interactive messages, Live outreach
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
342
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01527149
View directory record Official record
Conditions
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ofatumumab, Vincristine Sulfate
Procedure · Drug · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
2
States / cities
Buffalo, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2Phase 3 Interventional

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

NCT04349410
View directory record Official record
Conditions
CoVid 19 Positive
Interventions
Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
Drug
Lead sponsor
The Camelot Foundation
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 14, 2026, 11:23 PM EDT
Active, not recruiting Not applicable Interventional

Prebiotic Treatment in People With Schizophrenia

NCT05527210
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Prebiotic, Placebo Prebiotic
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Prebiotics, Gut Microbiota, and Cardiometabolic Health

NCT02346838
View directory record Official record
Conditions
Prediabetes
Interventions
Inulin, Placebo
Dietary Supplement
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
40 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women

NCT00421408
View directory record Official record
Conditions
Bone Resorption, Osteoporosis
Interventions
Whey protein supplement, Placebo
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
60 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Farmington, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Lycopene on High Risk Prostatic Tissue

NCT01443026
View directory record Official record
Conditions
Intraepithelial Prostatic Neoplasia, Prostatic Neoplasms
Interventions
Lycopene 30mg, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

NCT00002943
View directory record Official record
Conditions
Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glycemic Index and Brain Function

NCT01064778
View directory record Official record
Conditions
Obesity
Interventions
Low GI, High GI
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

NCT01336608
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Food is Medicine: Pilot Study

NCT06797453
View directory record Official record
Conditions
Weight Loss
Interventions
Shared Medical Visits, Full Plate Living
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

NCT03012061
View directory record Official record
Conditions
Asthma
Interventions
Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
19
States / cities
Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 14, 2026, 11:23 PM EDT
Active, not recruiting Not applicable Interventional

Early Intervention in Cognitive Aging

NCT02751866
View directory record Official record
Conditions
Overweight, Obesity and Other Hyperalimentation (E65-E68)
Interventions
Berry fruit powder OR nutritional ketosis, Placebo powder OR higher carbohydrate
Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
50 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Results available

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

NCT01124422
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 14, 2026, 11:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Physiological Chronobiome Modified by Age, Sex and Under Evoked Conditions

NCT04225442
View directory record Official record
Conditions
Healthy, Healthy Aging
Interventions
Fatty meal to challenge the physiological chronobiome in healthy young and old
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes

NCT03885245
View directory record Official record
Conditions
Asthma, Obesity
Interventions
L-ctirulline, Matching Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT04629170
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
SYNB8802, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 14, 2026, 11:23 PM EDT